Antibody-Coated Nanoparticles Steer mRNA Therapies Past the Liver to Reach Lungs, T Cells, and Beyond

Lipid nanoparticles carry mRNA and other nucleic acid drugs, but after intravenous injection they are mostly taken up passively by the liver. Reaching other tissues or hard-to-transfect cells therefore often requires high doses, which raises cost and safety concerns. Better targeting is a key step toward using genetic medicines for age-related and chronic diseases beyond liver disorders.

This paper is a laboratory protocol, not a clinical study. The authors describe how to make targeted LNPs (tLNPs) by labeling whole antibodies or antibody fragments and conjugating them to pre-formed LNPs. The protocol also covers purification, characterization, and in vivo and ex vivo evaluation of targeting. The stated timeline is about 0.5-1 day for antibody preparation, 1-2 days for conjugation, 1 day for purification and characterization, and 3-4 days for targeting assessment.

The authors report three demonstrations. In mice, anti-PECAM-1 antibodies on lung-tropic LNPs increased lung transfection about five-fold versus nontargeted LNPs. Anti-EGFR antibodies on liver-tropic LNPs increased liver transfection about 20-fold. In primary human T cells ex vivo, anti-CD5 conjugation raised LNP uptake 4.5-fold and significantly increased mRNA transfection.

The implication is that receptor-mediated targeting can raise the share of particles reaching the intended cells, which may allow comparable protein expression at lower doses. Because the method is described as compatible with any LNP formulation or antibody, it could be adapted to many targets.

Caveats: only the abstract was available, so detailed data, controls, and safety measurements could not be assessed. The results come from mouse and cell-culture models, and the reported fold-changes are illustrative demonstrations rather than clinical outcomes. The senior author discloses patent applications related to LNP technology.